2007 News Archive
- December 18
Discovery Parks
Discovery Parks Welcomes Private Equity Professional
Venture Capitalist Darrell Elliott joins Board; Dr. Bernie Bressler Promoted to Chair
- December 17
Chemokine Therapeutics
Chemokine Therapeutics announces new directors
- December 10
Chemokine Therapeutics
Chemokine Therapeutics continues patient therapy using CTCE-9908 and extends closing of its phase I/II clinical trial
- October 26
Chemokine Therapeutics
Chemokine Therapeutics investigator present encouraging preliminary results from CTCE-9908 Phase I/II clinical trial
- October 15
Neuromed
Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
- October 10
Chemokine Therapeutics
Two additional abstracts accepted for presentation at the upcomining Molecular Targets and Cancer Therapeutics International Conference
- October 5
Neuromed
Neuromed President & CEO Dr. Christopher Gallen Named Finalist for Scrip Award's "Executive of the Year"
- October 2
Chemokine Therapeutics
Chemokine Therapeutics completes patient recruitment of CTCE-9908 Phase I/II clinical trial
- September 19
Chemokine Therapeutics
Juravinski Cancer Centre investigator to present Phase I/II Data at the Molecular targets ....
- August 21
Neuromed
Neuromed Raises US$53.3 Million in Series E Financing to Accelerate Development of Pain Treatments
- August 8
Neuromed
Neuromed Announces that Merck & Co., Inc. Discontinues Development of Pain Drug Candidate, Joint Research Program Continues
- August 2
Neuromed
Neuromed Appoints Mario Orlando as Vice President of Marketing
- July 9
Neuromed
Neuromed Appoints Dr. William L. Hunter as Chairman of the Board of Directors
- Jun 19
Neuromed
Neuromed President & CEO Dr. Christopher Gallen named "100 Most Inspiring People in the Life Sciences Industry"
- May 30
Chemokine Therapeutics
Chemokine Therapeutics files for a public offering of units
- April 24
Neuromed
Neuromed licenses Phase 3 Chronic Pain Products from ALZA Corporation
- March 22
Chemokine Therapeutics
Chemokine Therapeutics announces addition to senior management team
- March 12
Chemokine Therapeutics
Chemokine Therapeutics announces preliminary results of CTCE-9908 Phase IB/II Clinical trial in late stage cancer patients